According to data released by LSEG Deals Intelligence, the healthcare sector saw a 35% increase on last year’s deals, reaching $174.6 billion in the first half of 2023 – a
AstraZeneca and partner Daiichi Sankyo have their first phase 3 data for TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) – in lung cancer –
Eiger BioPharmaceuticals has said it will cut staffing numbers by 25% and refocus its R&D activities on metabolic diseases, after the FDA said it would need a new stud
